AccScience Publishing / AN / Volume 2 / Issue 1 / DOI: 10.36922/an.290
Cite this article
101
Download
1644
Views
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
REVIEW

Treatment of Parkinson’s disease with piribedil: Suggestions for clinical practices

Cheng Jie Mao1 Chan Piu2 Li Rong Jin3 Li Juan Wang4 Olivier Rascol5* Chun Feng Liu1*
Show Less
1 Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu, China
2 Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing 100053, China
3 Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
4 Department of Neurology, Guangdong Provincial Peoples’ Hospital, Guangzhou 510080, Guangdong, China
5 Clinical Investigation Center CIC1436, Departments of Clinical Pharmacology and Neurosciences, NS-Park/FCRIN network and NeuroToul Center of Excellence for Neurodegeneration, INSERM, University Hospital of Toulouse and University of Toulouse, Toulouse, France
Advanced Neurology 2023, 2(1), 290 https://doi.org/10.36922/an.290
Submitted: 14 December 2022 | Accepted: 16 January 2023 | Published: 10 February 2023
© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

With rapidly growing rates of prevalence, disability, and mortality, Parkinson’s disease (PD) has become a global healthcare burden. Increasing elderly population increases the incidence of neurodegenerative diseases in China. Hence, PD poses a huge burden to Chinese economic and healthcare system. PD is a movement disorder that affects the motor and nonmotor functions. Dopamine agonists are used in the management of PD. Piribedil is an antiparkinsonian drug and piperazine derivative, which acts as D2/D3 receptor agonist. Piribedil is one of the non-ergot dopamine receptor (DR) agonists and has been used in China for many years as monotherapy or in combination with levodopa. In this paper, we present a review of clinical application of piribedil, management of adverse events, and drug interactions, and discuss the results of clinical trials of piribedil on motor and non-motor symptoms of PD.

Keywords
Neurodegenerative disease
Levodopa
Dopamine receptor
Non-ergot dopamine receptor agonists
α2-adrenoreceptor
Dyskinesia
Hypotension orthostatic
Funding
None.
References
[1]

Ascherio A, Schwarzschild MA, 2016 The epidemiology of Parkinson’s disease: Risk factors and prevention. Lancet Neurol, 15: 1257–1272. https://doi.org/10.1016/S1474-4422(16)30230-7 

[2]

Pringsheim T, Jette N, Frolkis A, et al., 2014, The prevalence of Parkinson’s disease: A systematic review and meta-analysis. Mov Disord, 29: 1583–1590. https://doi.org/10.1002/mds.25945

[3]

Delamarre A, Meissner WG, 2017, Epidemiology, environmental risk factors and genetics of Parkinson’s disease. Presse Med, 46: 175–181. https://doi.org/10.1016/j.lpm.2017.01.001

[4]

Li G, Ma J, Cui S, et al., 2019, Parkinson’s disease in China: A forty-year growing track of bedside work. Transl Neurodegeneration, 8: 22. 

[5]

Zheng Z, Zhu Z, Zhou C, et al., 2022, Burden of Parkinson disease in China, 1990-2019: Findings from the 2019 Global Burden of Disease Study. United States: NED. p.1–13.

[6]

GBD 2016 Parkinson’s Disease Collaborators, 2018, Global, regional, and national burden of Parkinson’s disease, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol, 17: 939–953. https://doi.org/10.1016/S1474-4422(18)30295-3

[7]

Moustafa AA, Chakravarthy S, Phillips JR, et al., 2016, Motor symptoms in Parkinson’s disease: A unified framework. Neurosci Biobehav Rev, 68: 727–740. https://doi.org/10.1016/j.neubiorev.2016.07.010

[8]

Church FC, 2021, Treatment options for motor and non-motor symptoms of Parkinson’s disease. Biomolecules, 11: 612. https://doi.org/10.3390/biom11040612

[9]

Poewe W, 2008, Non-motor symptoms in Parkinson’s disease. Eur J Neurol, 15: 14–20. https://doi.org/10.1111/j.1468-1331.2008.02056.x

[10]

Müller B, Assmus J, Herlofson K, et al., 2013, Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson’s disease. Parkinsonism Relat Disord, 19: 1027–1032. https://doi.org/10.1016/j.parkreldis.2013.07.010 

[11]

Rajiah K, Maharajan MK, Yeen SJ, et al., 2017, Quality of life and caregivers’ burden of Parkinson’s disease. Neuroepidemiology, 48: 131–137. https://doi.org/10.1159/000479031 

[12]

Pilipovich AA, Golubev VL, 2017, The agonist of dopamine receptors piribedil in treatment of Parkinson’s disease. Zh Nevrol Psikhiatr Im S S Korsakova, 117: 83–90. https://doi.org/10.17116/jnevro20171176183-90

[13]

Chen S, Chen H, 2020, Chinese Parkinson’s disease and movement disorder society Chinese guidelines for the treatment of Parkinson’s disease (fourth edition). Chin J Neurol, 53: 973–986.

[14]

NICE Guideline [NG71]-Parkinson’s Disease in Adults. Parkinson’s UK. Available from: https://www.parkinsons. org.uk/professionals/resources/nice-guideline-ng71- parkinsons-disease-adults [Last accessed on 2021 May 22].

[15]

Ferreira JJ, Katzenschlager R, Bloem BR, et al., 2013, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol, 20: 5–15. https://doi.org/10.1111/j.1468-1331.2012.03866.x

[16]

Thobois S, 2006, Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson’s disease: A review of the literature. Clin Ther, 28: 1–12. https://doi.org/10.1016/j.clinthera.2005.12.003

[17]

Millan MJ, 2010, From the cell to the clinic: A comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson’s disease. Pharmacol Ther, 128: 229–273. https://doi.org/10.1016/j.pharmthera.2010.06.002 

[18]

Burbulla LF, Song P, Mazzulli JR, et al., 2017, Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science, 357: 1255–1261. https://doi.org/10.1126/science.aam9080

[19]

García-Sanz P, Orgaz L, Bueno-Gil G, et al., 2017, N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson’s disease. Mov Disord, 32: 1409–1422. https://doi.org/10.1002/mds.27119 

[20]

Mosharov EV, Larsen KE, Kanter E, et al., 2009, Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron, 62: 218–229. https://doi.org/10.1016/j.neuron.2009.01.033

[21]

Fouillet A, Levet C, Virgone A, et al., 2012, ER stress inhibits neuronal death by promoting autophagy. Autophagy, 8: 915–926. https://doi.org/10.4161/auto.19716

[22]

Valdés P, Mercado G, Vidal RL, et al., 2014, Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1. Proc Natl Acad Sci U S A, 111: 6804–6809. https://doi.org/10.1073/pnas.1321845111

[23]

Cai Y, Arikkath J, Yang L, et al., 2016, Interplay of endoplasmic reticulum stress and autophagy in neurodegenerative disorders. Autophagy, 12: 225–244. https://doi.org/10.1080/15548627.2015.1121360

[24]

Xilouri M, Brekk OR, Polissidis A, et al., 2016, Impairment of chaperone-mediated autophagy induces dopaminergic neurodegeneration in rats. Autophagy, 12: 2230–2247. https://doi.org/10.1080/15548627.2016.1214777 

[25]

Beaulieu JM, Gainetdinov RR, 2011, The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev, 63: 182–217. https://doi.org/10.1124/pr.110.002642

[26]

Yang P, Perlmutter JS, Benzinger TL, et al., 2020, Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment? Ageing Res Rev, 57: 100994. https://doi.org/10.1016/j.arr.2019.100994

[27]

Jenner P, 1992, Parkinson’s disease: Pathological mechanisms and actions of piribedil. J Neurol, 239: S2–S8. https://doi.org/10.1007/BF00819559

[28]

Millan MJ, Cussac D, Milligan G, et al., 2001, Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)- adrenoceptors: Cellular and functional characterization. J Pharmacol Exp Ther, 297: 876–887.

[29]

Perez-Lloret S, Rascol O, 2016, Piribedil for the treatment of  motor and non-motor symptoms of Parkinson disease. CNS Drugs, 30: 703–717. https://doi.org/10.1007/s40263-016-0360-5 

[30]

Mittur A, 2011, Piribedil: Antiparkinsonian properties and potential clinical utility in dopaminergic disorders. Curr Drug Ther, 6: 17–34.

[31]

Lebrun-Frenay C, Borg M, 2002, Choosing the right dopamine agonist for patients with Parkinson’s disease. Curr Med Res Opin, 18: 209–214. https://doi.org/10.1185/030079902125000741

[32]

Nyholm D, 2006, Pharmacokinetic optimisation in the treatment of Parkinson’s disease : An update. Clin Pharmacokinet, 45: 109–136. https://doi.org/10.2165/00003088-200645020-00001 

[33]

Stocchi F, 2009, The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson’s disease. Parkinsonism Relat Disord, 15: S68–S71. https://doi.org/10.1016/S1353-8020(09)70784-9

[34]

Peihua L, Jianqin W, 2018, Clinical effects of piribedil in adjuvant treatment of Parkinson’s disease: A meta-analysis. Open Med (Wars), 13: 270–277. https://doi.org/10.1515/med-2018-0041

[35]

Brainin M, Barnes M, Baron JC, et al., 2004, Guidance for the preparation of neurological management guidelines by EFNS scientific task forces--revised recommendations 2004. Eur J Neurol, 11: 577–581. https://doi.org/10.1111/j.1468-1331.2004.00867.x

[36]

Evidente VG, Esteban RP, Domingo FM, et al., 2003, Piribedil as an adjunct to levodopa in advanced Parkinson’s disease: The Asian experience. Parkinsonism Relat Disord, 10: 117–121. https://doi.org/10.1016/s1353-8020(03)00096-8

[37]

Gong X, Zhang L, Wang J, 2016, The efficacy of levodopa and benserazide combined piribedil in the treatment of Parkinson’s disease. Clin Res Pract, 1: 86–87. 

[38]

Castro-Caldas A, Delwaide P, Jost W, et al., 2006, The Parkinson-control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson’s disease. Mov Disord, 21: 500–509. https://doi.org/10.1002/mds.20750 

[39]

Rascol O, Dubois B, Caldas AC, et al., 2006, Early piribedil monotherapy of Parkinson’s disease: A planned seven-month report of the REGAIN study. Mov Disord, 21: 2110–2115. https://doi.org/10.1002/mds.21122 

[40]

Rondot P, Ziegler M, 1992, Activity and acceptability of piribedil in Parkinson’s disease: A multicentre study. J Neurol, 239: S28–S34. https://doi.org/10.1007/BF00819564

[41]

Suwantamee J, Nidhinandana S, Srisuwananukorn S, et al., 2004, Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson’s disease: A 6-month open study. J Med Assoc Thai, 87: 1293–1300.

[42]

Ziegler M, Castro-Caldas A, Del Signore S, et al., 2003, Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson’s disease: A 6-month, randomized, placebo-controlled study. Mov Disord, 18: 418–425. https://doi.org/10.1002/mds.10359

[43]

Cheng YB, Qian JJ, Mao CJ, et al., Influence of piribedil on non-motor symptoms in early Parkinson’s Disease. Chin J Clin Neurosci, 15: 119–122.

[44]

Eggert K, Öhlwein C, Kassubek J, et al., 2014, Influence of the nonergot dopamine agonist piribedil on vigilance in patients with Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): An 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol, 37: 116–122. https://doi.org10.1097/WNF.0000000000000041

[45]

Mentenopoulos G, Katsarou Z, Bostantjopoulou S, et al., 1989, Piribedil therapy in Parkinson’s disease. Use of the drug in the retard form. Clin Neuropharmacol, 12: 23–28.

[46]

Nagaraja D, Jayashree S, 2001, Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry, 158: 1517–1519. https://doi.org/10.1176/appi.ajp.158.9.1517

[47]

Thobois S, Lhommée E, Klinger H, et al., 2013, Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain, 136: 1568–1577. https://doi.org/10.1093/brain/awt067

[48]

Lokk J, Delbari A, 2012, Clinical aspects of palliative care in advanced Parkinson’s disease. BMC Palliat Care, 11: 20. https://doi.org/10.1186/1472-684X-11-20

[49]

Thobois S, Ardouin C, Lhommée E, et al., 2010, Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: Predictors and underlying mesolimbic denervation. Brain, 133: 1111–1127. https://doi.org/10.1093/brain/awq032

[50]

Vale S, 2008, Current management of the cognitive dysfunction in Parkinson’s disease: How far have we come? Exp Biol Med (Maywood), 233: 941–951. https://doi.org/10.3181/0707-MR-193

[51]

Richard IH, 2006, Apathy does not equal depression in Parkinson disease: Why we should care. Neurology, 67: 10–11. https://doi.org/10.1212/01.wnl.0000231141.03382.92

[52]

Aarsland D, Påhlhagen S, Ballard CG, et al., 2011, Depression in Parkinson disease--epidemiology, mechanisms and management. Nat Rev Neurol, 8: 35–47. https://doi.org/10.1038/nrneurol.2011.189

[53]

Smith LA, Jackson MJ, Johnston L, et al., 2006, Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clin Neuropharmacol, 29: 112–125. https://doi.org/10.1097/01.WNF.0000220818.71231.DF

[54]

Uppuluri CT, Ravi PR, Dalvi AV, 2021, Design, optimization and pharmacokinetic evaluation of Piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson’s disease. Int J Pharm, 606: 120881. https://doi.org/10.1016/j.ijpharm.2021.120881

[55]

TRIVASTAL® 50 mg L.P, Prolonged-Release Coated Tablet. Available from: https://www.servier.ci/sites/default/files/ spc-pil/spc_trivastal_50mg.pdf

[56]

Yüksel K, Tuğlular I, 2019, Critical review of European medicines agency (EMA) assessment report and related literature on domperidone. Int J Clin Pharm, 41: 387–390. https://doi.org/10.1007/s11096-019-00803-9

[57]

Homann CN, Wenzel K, Suppan K, et al., 2002, Sleep attacks in patients taking dopamine agonists: Review. BMJ, 324: 1483–1487. https://doi.org/10.1136/bmj.324.7352.1483 

[58]

Perez-Lloret S, Rascol O, 2010, Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease. CNS Drugs, 24: 941–968. https://doi.org/10.2165/11537810-000000000-00000

[59]

Zhang P, Li Y, Nie K, et al., 2018, Hypotension and bradycardia, a serious adverse effect of piribedil, a case report and literature review. BMC Neurol, 18: 221. https://doi.org/10.1186/s12883-018-1230-1

[60]

Seppi K, Ray Chaudhuri K, Coelho M, et al., 2019, Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord, 34: 180–198. https://doi.org/10.1002/mds.27602

[61]

Lahrmann H, Cortelli P, Hilz M, et al., 2006, EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol, 13: 930–936. https://doi.org/10.1111/j.1468-1331.2006.01512.x

[62]

Micheli FE, Giugni JC, Espinosa ME, et al., 2015, Piribedil and pathological gambling in six Parkinsonian patients. Arq Neuropsiquiatr, 73: 115–118. https://doi.org/10.1590/0004-282X20140212 

[63]

Perez-Lloret S, Bondon-Guitton E, Rascol O, et al., 2010, Adverse drug reactions to dopamine agonists: A comparative study in the French Pharmacovigilance Database. Mov Disord, 25: 1876–1880. https://doi.org/10.1002/mds.23204 

[64]

Stamey W, Jankovic J, 2008, Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist, 14: 89–99. https://doi.org/10.1097/NRL.0b013e31816606a7

[65]

Giugni JC, Tschopp L, Escalante V, et al., 2012, Dose-dependent impulse control disorders in piribedil overdose. Clin Neuropharmacol, 35: 49–50. https://doi.org/10.1097/WNF.0b013e31823d78ab 

[66]

Tschopp L, Salazar Z, Botello MT, et al., 2010, Impulse control disorder and piribedil: Report of 5 cases. Clin Neuropharmacol, 33: 11–13. https://doi.org/10.1097/WNF.0b013e3181c4ae2e 

[67]

Perez-Lloret S, Rey MV, Fabre N, et al., 2012, Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol, 35: 261–265. https://doi.org/10.1097/WNF.0b013e31826e6e6d 

[68]

Samuel M, Rodriguez-Oroz M, Antonini A, et al., 2015, Management of impulse control disorders in Parkinson’s disease: Controversies and future approaches. Mov Disord, 30: 150–159. https://doi.org/10.1002/mds.26099

[69]

Weintraub D, 2008, Dopamine and impulse control disorders in Parkinson’s disease. Ann Neurol, 64: S93–S100. https://doi.org/10.1002/ana.21454 

[70]

Patel RS, Bhela J, Tahir M, et al., 2019, Pimavanserin in Parkinson’s Disease-induced Psychosis: A Literature Review. Cureus, 11: e5257. https://doi.org/10.7759/cureus.5257

[71]

Xiao-Ying G, Li Z, Ji-Heng W, et al., 2016, The efficacy of levodopa and benserazide combined piribedil in the treatment of Parkinson’s disease. Clin Res Pract, 1: 86–87.

[72]

Yan-Bo C, Jin-Jun Q, Cheng-Jie M, et al., 2007, Influence of Piribedil on non-motor symptoms in early Parkinson’s Disease. Chinese J Clin Neurosci, 15: 119–122.

Conflict of interest
The authors declare no financial or other conflicts of interest.
Share
Back to top
Advanced Neurology, Electronic ISSN: 2810-9619 Published by AccScience Publishing